X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare PLETHICO PHARMA with Wockhardt - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs WOCKHARDT LTD. - Comparison Results

WOCKHARDT LTD. 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA WOCKHARDT LTD. PLETHICO PHARMA/
WOCKHARDT LTD.
 
P/E (TTM) x -1.1 -11.8 - View Chart
P/BV x 0.0 2.4 0.7% View Chart
Dividend Yield % 0.0 1.4 -  

Financials

 PLETHICO PHARMA   WOCKHARDT LTD.
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
WOCKHARDT LTD.
Mar-17
PLETHICO PHARMA/
WOCKHARDT LTD.
5-Yr Chart
Click to enlarge
High Rs3951,129 35.0%   
Low Rs31627 5.0%   
Sales per share (Unadj.) Rs604.4363.1 166.4%  
Earnings per share (Unadj.) Rs32.5-20.4 -158.8%  
Cash flow per share (Unadj.) Rs51.3-7.0 -735.8%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.1 0.0%  
Book value per share (Unadj.) Rs473.6301.8 156.9%  
Shares outstanding (eoy) m34.08110.55 30.8%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x0.42.4 14.6%   
Avg P/E ratio x6.6-42.9 -15.3%  
P/CF ratio (eoy) x4.2-125.9 -3.3%  
Price / Book Value ratio x0.52.9 15.5%  
Dividend payout %0-48.9 0.0%   
Avg Mkt Cap Rs m7,26297,063 7.5%   
No. of employees `000NA6.8 0.0%   
Total wages/salary Rs m1,5969,665 16.5%   
Avg. sales/employee Rs ThNM5,931.8-  
Avg. wages/employee Rs ThNM1,428.1-  
Avg. net profit/employee Rs ThNM-334.0-  
INCOME DATA
Net Sales Rs m20,59840,146 51.3%  
Other income Rs m3861,143 33.8%   
Total revenues Rs m20,98441,289 50.8%   
Gross profit Rs m2,818128 2,201.3%  
Depreciation Rs m6421,489 43.1%   
Interest Rs m1,5932,253 70.7%   
Profit before tax Rs m969-2,472 -39.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-138-211 65.6%   
Profit after tax Rs m1,107-2,260 -49.0%  
Gross profit margin %13.70.3 4,290.4%  
Effective tax rate %-14.38.5 -167.3%   
Net profit margin %5.4-5.6 -95.4%  
BALANCE SHEET DATA
Current assets Rs m18,87746,160 40.9%   
Current liabilities Rs m11,89619,258 61.8%   
Net working cap to sales %33.967.0 50.6%  
Current ratio x1.62.4 66.2%  
Inventory Days Days36101 35.7%  
Debtors Days Days19894 210.3%  
Net fixed assets Rs m9,86140,165 24.5%   
Share capital Rs m341553 61.6%   
"Free" reserves Rs m12,33132,814 37.6%   
Net worth Rs m16,13933,367 48.4%   
Long term debt Rs m4,70631,903 14.8%   
Total assets Rs m33,14689,687 37.0%  
Interest coverage x1.6-0.1 -1,655.4%   
Debt to equity ratio x0.31.0 30.5%  
Sales to assets ratio x0.60.4 138.8%   
Return on assets %8.10 -94,883.1%  
Return on equity %6.9-6.8 -101.2%  
Return on capital %12.3-0.3 -3,666.1%  
Exports to sales %21.40-   
Imports to sales %15.20-   
Exports (fob) Rs m4,402NA-   
Imports (cif) Rs m3,136NA-   
Fx inflow Rs m4,4029,121 48.3%   
Fx outflow Rs m3,1842,133 149.3%   
Net fx Rs m1,2196,988 17.4%   
CASH FLOW
From Operations Rs m2,437-2,695 -90.5%  
From Investments Rs m-6,265-6,863 91.3%  
From Financial Activity Rs m2,49012,545 19.8%  
Net Cashflow Rs m-1,3373,010 -44.4%  

Share Holding

Indian Promoters % 82.7 74.5 111.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.3 2.3 187.0%  
FIIs % 5.5 7.7 71.4%  
ADR/GDR % 0.0 0.1 -  
Free float % 7.5 15.4 48.7%  
Shareholders   10,665 67,757 15.7%  
Pledged promoter(s) holding % 85.7 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   NOVARTIS  TORRENT PHARMA  STRIDES SHASUN LTD  STERLING BIOTECH  ASTRAZENECA PHARMA  

Compare PLETHICO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Flat; Metal Stocks Drag(09:30 am)

Asian share markets slipped in the opening trade today as investors digested the escalation in trade tensions between the US and China after both countries announced tariffs last week.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

Why Bank-Mergers Continue to Remain a Bad Idea(Vivek Kaul's Diary)

Jun 5, 2018

A newsreport suggests that the government plans to merge four public sector banks. We think it's a bad idea.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA - STERLING BIOTECH COMPARISON

COMPARE PLETHICO PHARMA WITH

MARKET STATS